The Journal of Pediatrics
Volume 153, Issue 3 , Pages 308-313 , September 2008

Newborn Screening for Cystic Fibrosis: A Lesson in Public Health Disparities

  • Lainie Friedman Ross, MD, PhD

      Affiliations

    • Corresponding Author InformationReprint requests: Lainie Friedman Ross, MD, PhD, University of Chicago, Department of Pediatrics, 5841 S. Maryland Ave, MC 6082, Chicago IL 60637

Received 21 November 2007 ,Revised 31 March 2008 ,Accepted 24 April 2008.

References 

  1. Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children. Minutes. http://mchb.hrsa.gov/programs/genetics/committee/Accessed January 11, 2008
  2. Newborn Screening: Toward a Uniform Screening Panel and System. http://mchb.hrsa.gov/screening/Accessed January 11, 2008
  3. Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR. 2004;53(RR-13):1–36
  4. Wilfond BS, Gollust GE. Policy issues for expanding newborn screening programs: the cystic fibrosis newborn screening experience in the United States. J Pediatr. 2005;146:668–674
  5. March of Dimes (Newborn Screening (United States). Cystic Fibrosis). Last updated January 3, 2008 http://www.marchofdimes.com/peristats/level1.aspx?reg=99&top=12&stop=239&lev=1&slev=1&obj=20Accessed January 11, 2008
  6. Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J, et al. A survey of newborn screening for cystic fibrosis in Europe. J Cystic Fibrosis. 2007;6:57–65
  7. Massie J, Clements B Australian Paediatric Respiratory Group. Diagnosis of cystic fibrosis after newborn screening: the Australasian experience-twenty years and five million babies later: a consensus statement from the Australasian Paediatric Respiratory Group. Pediatr Pulmonol. 2005;39:440–446
  8. Young SS, Kharrazi M, Pearl M, Cunningham G. Cystic fibrosis screening in newborns: results from existing programs. Curr Opin Pulmonary Med. 2001;7:427–433
  9. Wilfond B, Rothenberg LS. Ethical issues in cystic fibrosis newborn screening: from data to public health policy. Curr Opin Pulmonary Med. 2002;8:529–534
  10. Bonham JR, Downing M, Dalton A. Screening for cystic fibrosis: the practice and the debate. Eur J Pediatr. 2003;162(Suppl 1):S42–S45
  11. Dankert-Roelse JE, Merelle ME. Review of Outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe. J Pediatr. 2005;147:S15–S20
  12. Wilfond BS, Parad RB, Fost N. Balancing benefits and risks for cystic fibrosis newborn screening: implications for policy decisions. J Pediatr. 2005;147(3 Suppl):S109–S113
  13. Wagener JS, Sontag MK, Sagel SD. Accurso FJ (Update on newborn screening for cystic fibrosis). Curr Opin Pulmonary Med. 2004;10:500–504
  14. Botkin JR, Clayton EW, Fost NC, Burke W, Murray TH, Baily MA, et al. Newborn screening technology: proceed with caution. Pediatrics. 2006;117:1793–1799
  15. Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr. 1995;126:965–970
  16. Gregg RG, Simante A, Farrell PM, Koscik R, Kosorok MR, Laxova A, et al. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. Pediatrics. 1997;99:819–824
  17. Price JF. Newborn screening for cystic fibrosis: do we need a second IRT?. Arch Dis Childhood. 2006;91:209–210
  18. Narzi L, Lucarelli M, Lelli A, Grandoni F, Lo Cicero S, Ferraro A, et al. Comparison of two different protocols of neonatal screening for cystic fibrosis. Clin Genet. 2002;62:245–249
  19. Ross LF. Methodology matters. Am J Public Health. 2007;97:589
  20. Crossley J, Elliott R, Smith P. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet. 1979;8114:472–474
  21. Seltzer WK, Accurso F, Fall MZ, VanRiper AJ, Descartes M, Huang Y, et al. Screening for cystic fibrosis: feasibility of molecular genetic analysis of dried blood specimens. Biochem Med Metabolic Biol. 1991;46:105–109
  22. Braun AT, Farrell PM, Ferec C, Audrezet MP, Laxova A, Li Z, et al. Cystic fibrosis mutations and genotype-pulmonary phenotype analysis. J Cystic Fibrosis. 2006;5:33–41
  23. Petticrew MP, Sowden AJ, Lister-Sharp D, Wright K. False-negative results in screening programmes: systematic review of impact and implications. Health Technol Assess (Winchester, England). 2000;4(5):
  24. Yunis KA, Nasr MR, Lepejian G, Najjar S, Daher R. False-negative primary neonatal thyroid screening: the need for clinical vigilance and secondary screening. J Med Screening. 2003;10:2–4
  25. National Institutes of Health Consensus Development Conference. Genetic testing for cystic fibrosis. Arch Intern Med. 1999;159:1529–1539
  26. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med. 2004;6:387–391
  27. Spencer DA, Venkataraman M, Weller PH. Delayed diagnosis of cystic fibrosis in children from ethnic minorities. Lancet. 1998;342:238
  28. Doyle DL, Sanderson M, Bentvelzen J, Fineman RM. Factors which influence the rate of receiving a routine second newborn screening test in Washington State. Am J Med Genet. 1995;59:417–420
  29. Therrell BL, Adams J. Newborn screening in North America. J Inherited Metab Dis. 2007;30:447–465
  30. Sontag MK, Hammond KB, Zielenski J, Wagener JS, Accurso FJ. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr. 2005;147:S83–S88
  31. Murray J, Cuckle H, Taylor G, Littlewood J, Hewison J. Screening for cystic fibrosis. Health Technol Assess (Winchester, England). 1999;3(8):
  32. Moran J, Quirk K, Duff AJ, Brownlee KG. Newborn screening for CF in a regional paediatric centre: the psychosocial effects of false-positive IRT results on parents. J Cystic Fibrosis. 2007;6:250–254
  33. Maniatis AK, Taylor L, Letson GW, Bloch CA, Kappy MS, Zeitler P. Congenital hypothyroidism and the second newborn metabolic screening in Colorado, USA. J Pediatr Endocrinol. 2006;19:31–38
  34. Brosnan CA, Brosnan P, Therrell BL, Slater CH, Swint JM, Annegers JF, et al. A comparative cost analysis of newborn screening for classic congenital adrenal hyperplasia in Texas. Public Health Rep. 1998;113:170–178
  35. Tuerck J. Newborn screening program infrastructure: evaluation and tracking database for the long-term follow-up of infants identified by MS/MS newborn screening. Presented at the Secretary's Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children Summary of Third Meeting, Washington, DC, January 13-14, 2005 http://mchb.hrsa.gov/programs/genetics/committee/3rdmeeting.htmAccessed January 11, 2008
  36. Rock MJ, Mischler EH, Farrell PM, Bruns WT, Hassemer DJ, Laessig RH. Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test. Pediatr Pulmonol. 1989;6:42–48
  37. Cheillan D, Vercherat M, Cheavlier-Porst F, Charcosset M, Rolland MO, Dorche C. False positive results in neonatal screening for cystic fibrosis based on a three-stage protocol (IRT/DNA/IRT): Should we adjust IRT cut-off to ethnic origin?. J Inherited Metab Dis. 2005;28:813–818
  38. Baroni MA, Anderson YE, Mischler E. Cystic fibrosis newborn screening: impact of early screening results on parenting stress. Pediatr Nurs. 1997;23:143–151
  39. Lewis S, Curnow L, Ross M, Massie J. Parental attitudes to the identification of their infants as carriers of cystic fibrosis by newborn screening. J Paediatr Child Health. 2006;42:533–537
  40. Castellani C, Picci L, Scarpa M, Dechecchi MC, Zanolla L, Assael BM, et al. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers. Am J Med Genet. 2005;135:142–144
  41. Stone DH, Stewart S. Screening and the new genetics; a public health perspective on the ethical debate. J Public Health Med. 1996;18:3–5
  42. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med. 2001;3:149–154
  43. Dudding T, Wilcken B, Burgess B, Hambly J, Turner G. Reproductive decisions after neonatal screening identifies cystic fibrosis. Arch Dis Childhood Fetal Neonatal Ed. 2000;82:F124–F127
  44. Mischler EH, Wilfond BS, Fost N, Laxova A, Reiser C, Sauer CM, et al. Cystic fibrosis newborn screening: impact on reproductive behavior and implications for genetic counseling. Pediatrics. 1998;102:44–52
  45. Comeau AM, Parad R, Gerstle R, O'Sullivan BP, Dorkin HL, Dovey M, et al. Communications systems and their models: Massachusetts parent compliance with recommended specialty care after positive cystic fibrosis newborn screening result. J Pediatr. 2005;147(Suppl):S98–S100
  46. Giusti R, Badgwell A, Iglesias AD New York State Cystic Fibrosis Newborn Screening Consortium. New York State cystic fibrosis consortium: the first 2.5 years of experience with cystic fibrosis newborn screening in an ethnically diverse population. Pediatrics. 2007;119:e460–e467
  47. Tluczek A, Koscik RL, Modaff P, Pfeil D, Rock MJ, Farrell PM, et al. Newborn screening for cystic fibrosis: parents' preferences regarding counseling at the time of infants' sweat test. J Genet Counsel. 2006;15:277–291
  48. Oliver S, Dezateux C, Kavanagh J, Lempert T, Stewart R. Disclosing to parents newborn carrier status identified by routine blood spot screening. Cochrane Database Syst Rev. 2004;(4):CD003859
  49. American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion. Number 325, December 2005. Update on carrier screening for cystic fibrosis Obstet Gynecol. 2005;106:1465–1468
  50. Bennett R. Antenatal genetic testing and the right to remain in ignorance. Theoretical Med Bioethics. 2001;22:461–471
  51. Takala T, Hayry M. Genetic ignorance, moral obligations and social duties. J Med Philos. 2000;25:107–113
  52. Working Party of the Clinical Genetics Society (UK). The Genetic Testing of Children. J Med Genet. 1994;31:785–797
  53. American Society of Human Genetics (ASHG)/American College of Medical Genetics (ACMG). Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents. Am J Human Genet. 1995;57:1233–1241
  54. LeGrys VA, Wood RE. Incidence and implications of false-negative sweat test reports in patients with cystic fibrosis. Pediatr Pulmonol. 1988;4:169–172
  55. Doughty IM, Ward I, Schwarz M, David TJ. Delayed diagnosis of cystic fibrosis due to normal sweat electrolytes. J R Soc Med. 1995;88:417P–418P
  56. Fitzgerald D, Van Asperen P, Henry R, Waters D, Freelander M, Wilson M, et al. Delayed diagnosis of cystic fibrosis in children with a rare genotype (delta F508/R117H). J Paediatr Child Health. 1995;31:168–171
  57. Kammesheidt A, Kharrazi M, Graham S, Young S, Pearl M, Dunlop C, et al. Comprehensive genetic analysis of the cystic fibrosis transmembrane conductance regulator from dried blood specimens—Implications for newborn screening. Genet Med. 2006;8:557–562
  58. Bernhardt BA, Weiner J, Foster EC, Tumpson JE, Pyeritz RE. The economics of clinical genetics services (II. A time analysis of a medical genetics clinic). Am J Human Genet. 1987;41:559–565
  59. Sarles J, Berthezene P, Le Louarn C, Somma C, Perini JM, Catheline M, et al. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr. 2005;147:302–305
  60. Sarles J, Barthellemy S, Ferec C, Iovanna J, Roussey M, Farriaux JP, et al. Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed. 1999;80:F118–F122
  61. van den Akker-van Marle ME, Dankert HM, Verkerk PH, Dankert-Roelse JE. Cost-effectiveness of 4 Neonatal screening strategies for cystic fibrosis. Pediatrics. 2006;118:896–905
  62. Stone PW, Teutsch S, Chapman RH, Bell C, Goldie SJ, Neumann PJ. Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. Am J Prevent Med. 2000;19:15–23
  63. Sims EJ, Mugford M, Clark A, Aitken D, McCormick J, Metha G, et al. Cystic Fibrosis Database Steering Committee Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet. 2007;369:1187–1195
  64. Lee DS, Rosenberg JA, Peterson A, Makholm L, Hoffman G, Laessig RH, et al. Analysis of the Costs of Diagnosing Cystic Fibrosis with a Newborn Screening Program. J Pediatr. 2003;142:617–623
  65. Carroll AE, Downs SM. Comprehensive cost-utility analysis of newborn screening strategies. Pediatrics. 2006;117:S287–S295
  66. Wilson JMG, Jungner F. Principles and Practice of Screening for Disease (Public Health Papers, no. 34). Geneva: World Health Organization; 1968;
  67. Therrell BL. U.S. newborn screening policy dilemmas for the twenty-first century. Molec Genet Metab. 2001;74:64–74
  68. Pollitt RJ. International perspectives on newborn screening. J Inherited Metab Dis. 2006;29:390–396
  69. Dabrock P. Public Health Genetics and Social Justice. Commun Genet. 2006;9:34–39
  70. Cronin EK, Normand C, Henthorn JS, Hickman M, Davies SC. Costing model for neonatal screening and diagnosis of haemoglobinopathies. Arch Dis Child Fetal Neonatal Ed. 1998;79:F161–F167
  71. Grosse SD, Olney RS, Baily MA. The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: a critique. Appl Health Econ Health Policy. 2005;4:239–247
  72. Shafer FE, Lorey F, Cunningham GC, Klumpp C, Vichinsky E, Lubin B. Newborn screening for sickle cell disease: 4 years of experience from California's newborn screening program. J Pediatr Hematol/Oncol. 1996;18:36–41
  73. Henry RL, Boulton TJ, Roddick LG. False negative results on newborn screening for cystic fibrosis. J Paediatr Child Health. 1990;26:150–151
  74. Grosse SD, Boyle CA, Kenneson A, Khoury MJ, Wilfond BS. From public health emergency to public health service: the implications of evolving criteria for newborn screening panels. Pediatrics. 2006;117:923–929

 This study was funded by NIH grant R01 HD043455-01. The author declares no conflict of interest.

PII: S0022-3476(08)00371-5

doi: 10.1016/j.jpeds.2008.04.061

The Journal of Pediatrics
Volume 153, Issue 3 , Pages 308-313 , September 2008

Article Tools